Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes

Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes

(2014) A. P. Sykes et al.   DIABETES OBESITY & METABOLISM

Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

(2013) Elizabeth K Hussey et al.   BMC Pharmacology & Toxicology

Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus

(2012) Muhammad A. Abdul-Ghani et al.   Current Diabetes Reports

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2012) K. Stenlöf et al.   DIABETES OBESITY & METABOLISM

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients

(2011) R. L. Dobbins et al.   DIABETES OBESITY & METABOLISM

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET